Top Industry Leaders in the Urothelial Carcinoma Treatment Market
Latest Urothelial Carcinoma Treatment Companies Updates
Janssen Receives FDA Approval for TECENTRIQ (Atezolizumab) in Combination with AVASTIN (Bevacizumab) for the First-Line Treatment of Patients with Unresectable Locally Advanced or
Metastatic Urothelial Carcinoma: This October 2023 approval expands treatment options for advanced bladder cancer patients.
AstraZeneca Announces Positive Phase III Results for Encorafenib and Cetuximab Combination Therapy for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: This promising development in November 2023 could lead to a new first-line treatment option.
Pfizer Initiates Phase III Trial Evaluating Bavencio (Velvalumab) Plus Chemotherapy as a First-Line Treatment for Muscle-Invasive Urothelial Carcinoma: This ongoing trial investigates another potential first-line therapy.
List of Urothelial Carcinoma Treatment Key companies in the market:
- GlaxoSmithKline plc
- Genentech, Inc
- Novartis AG
- Dendreon
- Merck KGaA
- Eisai Co
- Sanofi S.A
- Bristol-Myers Squibb